Navigation Links
Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
Date:1/12/2011

HAYWARD, Calif., Jan. 12, 2011 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced the promotion of Thomas Yorkey, Ph.D., to Vice President of Research & Development, Dr. Yorkey will lead all global R&D initiatives and will report to Clint Carnell, Chief Operating Officer at Solta.

"Tom has made an immediate impact since joining the company, leading our advanced development initiatives," said Mr. Carnell.  "With more than 20 years of experience in the medical device industry, Tom possesses the leadership and technology development skills to aggressively lead our efforts in bringing to market new and innovative products and procedures that will benefit both our doctors and their patients around the world."

Dr. Yorkey has experience in leading companies from startups to multi-nationals which include Nellcor Puritan Bennett, a division of Tyco Healthcare where he served as VP of Research and Development. He holds a Ph.D. in Electrical Engineering from the University of Wisconsin, Madison and a Bachelor of Science degree in Electrical Engineering from the State University of New York at Buffalo.  Dr. Yorkey also sits on the Board of Directors of Hunter Technologies, a private Electronic Manufacturing Services company.

ABOUT SOLTA MEDICAL, INC.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the only FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.

© 2010 Solta Medical, Inc. All rights reserved. Thermage, Fraxel, Fraxel re:store, Isolaz and Solta Medical are trademarks or registered trademarks of Solta Medical, Inc. or its subsidiaries.


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
2. Solta Medical Reports Third Quarter 2010 Results
3. Solta Medical Announces FDA 510(k) Clearance of Fraxel re:store Dual Laser System for the Treatment of Actinic Keratosis
4. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
5. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
6. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
7. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
8. Solta Medical and Alma Lasers Resolve Patent Lawsuits
9. Solta Medical to Participate in 2nd Annual Lazard Capital Markets Medical Technology Conference
10. Solta Medical, Inc. Announces Fourth Quarter 2009 Results Release Date and Conference Call
11. Solta Medical Donates Fraxel re:store(R) Laser System to Grossman Burn Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017  Medical ... knowledge and skills while treating their patients. ... hands-on experience without involving patients. Simulation provides ... Clinicians can carry out procedures, refine techniques ... risk. Integration of new technology, such as ...
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring ... their closets. “They Sang At Her Funeral” is the creation of published author, Annalise ... five children and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to ...
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important milestones. To ... $835 million in resolved debt for its clients. , Credit card debt, unpaid hospital ... of debt settled by the company. With more than a decade of combined service ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... Texas as a part of its national Swirl: A Wine Tasting Event series ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has ... filter. When we’re born, Nature gives us a full supply of melanin – ... we continuously lose this natural glare-reducing pigment; however, around the age of thirty, we ...
Breaking Medicine News(10 mins):